CoraVie Medical CEO Aimee Garza and Dr. Michael Bloch, a hypertension specialist and clinical advisor for the startup, talk about why the healthcare industry needs a better approach to blood pressure monitoring. CoraVie is developing an implantable device that measures patients’ blood pressure, operating in a similar way to continuous glucose monitors. Watch or listen now!
This week, the FDA granted clearance to Withings’ BPM Pro 2 cellular blood pressure monitor. The device seeks to help providers scale remote patient monitoring for heart failure patients.
Yusuf Qasim, President of Payments Optimization at Zelis, discussed how the company is transforming healthcare payments from a fragmented, patchwork system into a modern, digital infrastructure.
Providence Health Plan and the American Heart Association will create blood pressure programs in 20 community organizations and clinics over three years.
CoraVie Medical, a startup developing an implantable continuous blood pressure monitor, recently won the medical devices track of MedCity News’ INVEST Pitch Perfect contest. The pre-revenue company’s remote management solution monitors for the early detection of dangerous blood pressure levels to prevent crises that could lead to heart attack, stroke, kidney failure or death.
Mineralys Therapeutics upsized its IPO, raising capital to finance clinical trial plans for a molecule that could become an alternative to currently available hypertension medicines. The Mineralys molecule takes a similar approach to a drug candidate that AstraZeneca is acquiring in a $1.3 billion deal.
CardieX, a cardiovascular technology company based in both Australia and Illinois, recently acquired Blumio, a San Mateo, California-based startup focused on cardiovascular sensors. The deal will advance both companies’ vision to accurately and easily measure blood pressure without relying on the use of a cuff.
Neurologists and health care practitioners must evolve with the world. Telemedicine carts assist in this evolution by serving as an intermediary between patients and doctors.
The Series D funding round was led by growth equity firm Stripes. Hello Heart's latest haul brings the total amount the company has raised since its founding in 2013 to $138 million.
A large study published in JAMA Network Open found that people with stage II hypertension were able to reduce their systolic blood pressure and maintain it over three years using Hello Heart’s app.
According to a report by the Wall Street Journal, Apple is planning to add more health features to its watch, including a feature to track blood pressure and a wrist-based thermometer.
Fitbit is launching a trial to see if its its newest smartwatch could use pulse arrival time to measure blood pressure. Other wearable companies have tried to add wrist-based blood pressure features to their devices, but so far, they have limited accuracy.
At a time when AI is reshaping pharma, Reverba Global CEO Cheryl Lubbert explained in an interview why empathy, context, and ethics still require a human touch.
Providing care for chronic disease patients during a one-in-a-century pandemic is full of challenges, but health systems like Jefferson Health are finding ways — with help from technology — to make sure their patients are getting the care they need.
Livongo has revealed a new voice-enabled blood pressure monitoring system, which is powered by Amazon Lex and Amazon Polly.
The pre-order price of the device is $499 and it will be available in retail stores starting in January.
Every digital health startup wants clinical validation, but studies have unexpected results. That's what appears to have greeted Medisafe when it ventured to gather real-world evidence about its mobile health tool.
Qardio's three products — QardioArm, QardioBase and QardioCore — have been integrated onto Tactio Health Group's digital platform.